ロルラチニブの中枢神経系副作用への対応に関する提言

Kaoru Kubota, Noriko Yanagitani, Eiki Ichihara, Tsubasa Ohkubo, Tatsuo Akechi

研究成果査読

抄録

‒‒ Objectives. Lorlatinib is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor indicated for the treatment of unresectable advanced or recurrent ALK fusion gene-positive non-small cell lung cancer, as demonstrated by its high efficacy in a global, randomized, phase III trial. The characteristic adverse drug reactions of lorlatinib include central nervous system (CNS) symptoms, such as cognitive impairment, language impairment, mood disorders, and hallucinations, which may require dose interruption or dose reduction depending on the severity of the symptoms. Therefore, pulmonologists and oncologists should exercise caution when diagnosing and treating CNS symptoms. We discussed the management policy for CNS symptoms caused by lorlatinib. Methods. Based on the psychiatrist’s review of the diagnosis and grading for patients with lorlatinib-induced CNS symptoms, pulmonologists and the psychiatrist discussed the policy for the management of CNS symptoms. Results. Considering the feasibility of diagnosing and managing lorlatinib-induced CNS symptoms, and the impact of symptoms on the patient’s daily life, a flow chart was developed. Conclusions. Regarding the management of CNS symptoms caused by lorlatinib, we propose an approach that basically involves dose interruption or dose reduction and referral to a psychiatrist if the impact on the patient’s daily life is significant.

寄稿の翻訳タイトルProposal for Handling Central Nervous System Symptoms Caused by Lorlatinib
本文言語Japanese
ページ(範囲)83-88
ページ数6
ジャーナルJapanese Journal of Lung Cancer
64
2
DOI
出版ステータスPublished - 4月 20 2024
外部発表はい

Keywords

  • Adverse drug reactions (ADRs)
  • Central nervous system symptoms
  • Lorlatinib
  • Non-small cell lung cancer (NSCLC)

ASJC Scopus subject areas

  • 腫瘍学
  • 呼吸器内科

フィンガープリント

「ロルラチニブの中枢神経系副作用への対応に関する提言」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル